针对三阴性乳腺癌进展和并发症的小分子 TLR4 拮抗剂的最新研究进展。

IF 3.3 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic & Medicinal Chemistry Pub Date : 2024-11-14 DOI:10.1016/j.bmc.2024.118000

Darsshen Ramana A.L. Kathirasan , Siti Nor ’Izzah Binti Normizan , Nurul Athirah Binti Mohd Salleh , Khor Poh-Yen

{"title":"针对三阴性乳腺癌进展和并发症的小分子 TLR4 拮抗剂的最新研究进展。","authors":"Darsshen Ramana A.L. Kathirasan , Siti Nor ’Izzah Binti Normizan , Nurul Athirah Binti Mohd Salleh , Khor Poh-Yen","doi":"10.1016/j.bmc.2024.118000","DOIUrl":null,"url":null,"abstract":"<div><div>Toll-like receptor 4 (TLR4) plays a vital role in the innate immune response, but its overactivation has been associated with several diseases, such as aggressive progression of triple-negative breast cancer (TNBC). As a result, inhibiting TLR4 has emerged as a potential therapeutic strategy for this challenging breast cancer subtype. This review summarizes recent advancements in the development of small-molecule TLR4 antagonists to suppress TNBC growth, metastasis, and chemotherapy resistance. We also examine their potential in managing cancer-related complications and propose future directions for their application in TNBC therapy.</div></div>","PeriodicalId":255,"journal":{"name":"Bioorganic & Medicinal Chemistry","volume":"116 ","pages":"Article 118000"},"PeriodicalIF":3.3000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recent progress on small molecule TLR4 antagonist against triple-negative breast cancer progression and complications\",\"authors\":\"Darsshen Ramana A.L. Kathirasan , Siti Nor ’Izzah Binti Normizan , Nurul Athirah Binti Mohd Salleh , Khor Poh-Yen\",\"doi\":\"10.1016/j.bmc.2024.118000\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Toll-like receptor 4 (TLR4) plays a vital role in the innate immune response, but its overactivation has been associated with several diseases, such as aggressive progression of triple-negative breast cancer (TNBC). As a result, inhibiting TLR4 has emerged as a potential therapeutic strategy for this challenging breast cancer subtype. This review summarizes recent advancements in the development of small-molecule TLR4 antagonists to suppress TNBC growth, metastasis, and chemotherapy resistance. We also examine their potential in managing cancer-related complications and propose future directions for their application in TNBC therapy.</div></div>\",\"PeriodicalId\":255,\"journal\":{\"name\":\"Bioorganic & Medicinal Chemistry\",\"volume\":\"116 \",\"pages\":\"Article 118000\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioorganic & Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0968089624004140\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0968089624004140","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Toll 样受体 4（TLR4）在先天性免疫反应中发挥着重要作用，但它的过度激活与多种疾病有关，如三阴性乳腺癌（TNBC）的侵袭性进展。因此，抑制 TLR4 已成为这一具有挑战性的乳腺癌亚型的潜在治疗策略。本综述总结了开发小分子 TLR4 拮抗剂以抑制 TNBC 生长、转移和化疗耐药性方面的最新进展。我们还研究了它们在控制癌症相关并发症方面的潜力，并提出了它们在 TNBC 治疗中应用的未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Recent progress on small molecule TLR4 antagonist against triple-negative breast cancer progression and complications

查看原文本刊更多论文

Recent progress on small molecule TLR4 antagonist against triple-negative breast cancer progression and complications

Toll-like receptor 4 (TLR4) plays a vital role in the innate immune response, but its overactivation has been associated with several diseases, such as aggressive progression of triple-negative breast cancer (TNBC). As a result, inhibiting TLR4 has emerged as a potential therapeutic strategy for this challenging breast cancer subtype. This review summarizes recent advancements in the development of small-molecule TLR4 antagonists to suppress TNBC growth, metastasis, and chemotherapy resistance. We also examine their potential in managing cancer-related complications and propose future directions for their application in TNBC therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Bioorganic & Medicinal Chemistry 医学-生化与分子生物学

CiteScore

6.80

自引率

2.90%

发文量

413

审稿时长

17 days

期刊介绍： Bioorganic & Medicinal Chemistry provides an international forum for the publication of full original research papers and critical reviews on molecular interactions in key biological targets such as receptors, channels, enzymes, nucleotides, lipids and saccharides. The aim of the journal is to promote a better understanding at the molecular level of life processes, and living organisms, as well as the interaction of these with chemical agents. A special feature will be that colour illustrations will be reproduced at no charge to the author, provided that the Editor agrees that colour is essential to the information content of the illustration in question.